Olipudase alfa: a new treatment for patients with ASMD
Chair: Eugen Mengel, Hochheim, Germany

Welcome and introduction
Eugen Mengel, Hochheim, Germany

Sphingomyelin accumulation – Pathology behind the disease: sphingomyelin accumulation and clinical manifestations
Nathalie Guffon, Bron, France

Olipudase alfa data – Investigating olipudase alfa in clinical trials: efficacy and safety
Maurizio Scarpa, Udine, Italy

ASMD/olipudase alfa clinical case – The treatment outcome: an ASMD patient case study
Eugen Mengel, Hochheim, Germany

Panel discussion and Q&A
All panel

Closing remarks
Eugen Mengel, Hochheim, Germany

---

sponsored by

Sanofi